79 related articles for article (PubMed ID: 21867423)
1. Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222.
Greene RJ; Tu H; Gibbs JP; Greg Slatter J
Xenobiotica; 2011 Nov; 41(11):945-57. PubMed ID: 21867423
[TBL] [Abstract][Full Text] [Related]
2. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
He H; Tran P; Yin H; Smith H; Batard Y; Wang L; Einolf H; Gu H; Mangold JB; Fischer V; Howard D
Drug Metab Dispos; 2009 Mar; 37(3):536-44. PubMed ID: 19074975
[TBL] [Abstract][Full Text] [Related]
3. Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs.
He H; Tran P; Yin H; Smith H; Flood D; Kramp R; Filipeck R; Fischer V; Howard D
Drug Metab Dispos; 2009 Mar; 37(3):545-54. PubMed ID: 19074976
[TBL] [Abstract][Full Text] [Related]
4. Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs.
Diez-Torrubia A; García-Aparicio C; Cabrera S; De Meester I; Balzarini J; Camarasa MJ; Velázquez S
J Med Chem; 2010 Jan; 53(2):559-72. PubMed ID: 20000418
[TBL] [Abstract][Full Text] [Related]
5. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.
Wang A; Dorso C; Kopcho L; Locke G; Langish R; Harstad E; Shipkova P; Marcinkeviciene J; Hamann L; Kirby MS
BMC Pharmacol; 2012 Apr; 12():2. PubMed ID: 22475049
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase IV dependent water-soluble prodrugs of highly lipophilic bicyclic nucleoside analogues.
Diez-Torrubia A; Balzarini J; Andrei G; Snoeck R; De Meester I; Camarasa MJ; Velázquez S
J Med Chem; 2011 Mar; 54(6):1927-42. PubMed ID: 21332170
[TBL] [Abstract][Full Text] [Related]
7. Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV.
Namoto K; Sirockin F; Ostermann N; Gessier F; Flohr S; Sedrani R; Gerhartz B; Trappe J; Hassiepen U; Duttaroy A; Ferreira S; Sutton JM; Clark DE; Fenton G; Beswick M; Baeschlin DK
Bioorg Med Chem Lett; 2014 Feb; 24(3):731-6. PubMed ID: 24439847
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl-peptidase-IV by cleaving neuropeptide Y induces lipid accumulation and PPAR-γ expression.
Rosmaninho-Salgado J; Marques AP; Estrada M; Santana M; Cortez V; Grouzmann E; Cavadas C
Peptides; 2012 Sep; 37(1):49-54. PubMed ID: 22819773
[TBL] [Abstract][Full Text] [Related]
9. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
[TBL] [Abstract][Full Text] [Related]
10. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
[TBL] [Abstract][Full Text] [Related]
11. Novel water-soluble prodrugs of acyclovir cleavable by the dipeptidyl-peptidase IV (DPP IV/CD26) enzyme.
Diez-Torrubia A; Cabrera S; de Castro S; García-Aparicio C; Mulder G; De Meester I; Camarasa MJ; Balzarini J; Velázquez S
Eur J Med Chem; 2013; 70():456-68. PubMed ID: 24185376
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Scheen AJ
Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects.
Ayalasomayajula SP; Dole K; He YL; Ligueros-Saylan M; Wang Y; Campestrini J; Humbert H; Sunkara G
Curr Med Res Opin; 2007 Dec; 23(12):2913-20. PubMed ID: 17931461
[TBL] [Abstract][Full Text] [Related]
14. ASP4000, a slow-binding dipeptidyl peptidase 4 inhibitor, has antihyperglycemic activity of long duration in Zucker fatty rats.
Tanaka-Amino K; Matsumoto K; Hatakeyama Y; Takakura S; Mutoh S
Acta Diabetol; 2010 Mar; 47(1):43-8. PubMed ID: 19238312
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure study and investigation of solid-state cyclization for AMG 222, a channel hydrate.
Kiang YH; Nagapudi K; Liu J; Staples RJ; Jona J
Int J Pharm; 2013 Jan; 441(1-2):299-306. PubMed ID: 23182974
[TBL] [Abstract][Full Text] [Related]
16. An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (R)-N-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subjects after multiple dosing.
Tonn GR; Wong SG; Wong SC; Johnson MG; Ma J; Cho R; Floren LC; Kersey K; Berry K; Marcus AP; Wang X; Van Lengerich B; Medina JC; Pearson PG; Wong BK
Drug Metab Dispos; 2009 Mar; 37(3):502-13. PubMed ID: 19088267
[TBL] [Abstract][Full Text] [Related]
17. Human nitrilase-like protein does not catalyze the hydrolysis of vildagliptin.
Asakura M; Nakano M; Hayashida K; Fujii H; Nakajima M; Atsuda K; Itoh T; Fujiwara R
Drug Metab Pharmacokinet; 2014; 29(6):463-9. PubMed ID: 25008847
[TBL] [Abstract][Full Text] [Related]
18. In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma.
Jost MM; Lamerz J; Tammen H; Menzel C; De Meester I; Lambeir AM; Augustyns K; Scharpé S; Zucht HD; Rose H; Jürgens M; Schulz-Knappe P; Budde P
Biochem Pharmacol; 2009 Jan; 77(2):228-37. PubMed ID: 18940185
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).
Brandt I; Joossens J; Chen X; Maes MB; Scharpé S; De Meester I; Lambeir AM
Biochem Pharmacol; 2005 Jul; 70(1):134-43. PubMed ID: 15907807
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of PKF275-055, a novel, selective, orally bioavailable, long-acting dipeptidyl peptidase IV inhibitor in streptozotocin-induced diabetic peripheral neuropathy.
Bianchi R; Cervellini I; Porretta-Serapiglia C; Oggioni N; Burkey B; Ghezzi P; Cavaletti G; Lauria G
J Pharmacol Exp Ther; 2012 Jan; 340(1):64-72. PubMed ID: 21984837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
